Co-biomodulation with arsenic trioxide in multiple myeloma

Leukemia Research

Volumn 25, Issue 3, 2001, Pages 237-239

  Gallagher, Robert E ^a  

^a ALBERT EINSTEIN CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ARSENIC TRIOXIDE; CD31 ANTIGEN; CD38 ANTIGEN; INTERCELLULAR ADHESION MOLECULE 1; LYMPHOCYTE FUNCTION ASSOCIATED ANTIGEN 1;

ACUTE MYELOBLASTIC LEUKEMIA; CYTOLYSIS; HUMAN; HUMAN CELL; LYMPHOKINE ACTIVATED KILLER CELL; MYELOMA CELL; NOTE; PRIORITY JOURNAL; PROTEIN EXPRESSION;

ADJUVANTS, IMMUNOLOGIC; ANTINEOPLASTIC AGENTS; ARSENICALS; DOSE-RESPONSE RELATIONSHIP, DRUG; HUMANS; KILLER CELLS, LYMPHOKINE-ACTIVATED; LEUKEMIA, PROMYELOCYTIC, ACUTE; MULTIPLE MYELOMA; OXIDES;

EID: 0035133852     PISSN: 01452126     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0145-2126(00)00144-2     Document Type: Note

References (27)

1. Control of apoptosis in hematopoiesis and leukemia by cytokines, tumor suppressor and oncogenes
2. Immunomodulation of cancer: potential use of selectively replicating agents
3. 3 exerts dose-dependent dual effects on APL cells
4. Arsenic trioxide induces dose- and time-dependent apoptosis of endothelium and may exert an antileukemic effect via inhibition of angiogenesis
5. Human CD38 (ADP-ribosyl cyclase) is a counter-receptor of CD31, and Ig superfamily member
6. Leukocytosis and the retinoic acid syndrome in patients with acute promyelocytic leukemia treated with arsenic trioxide
7. Arsenic trioxide causes selective necrosis in solid murine tumors by vascular shutdown
8. Modulation of leukemic cell sensitivity to lymphokine-activated killer cytolysis: role of intercellular adhesion molecule-1
9. Differentiation-related expression of adhesion molecules and receptors on human neuroblastoma tissues, cell lines and variants
10. Influence of malignant cell clonogenic capacities and position along the maturation pathway on their susceptibility to lymphokine-activated killer cell cytotoxicity
11. The role of human melanoma cell ICAM-1 expression on lymphokine activated killer cell-mediated lysis, and the effect of retinoic acid
12. All-trans retinoic acid inhibits the growth of breast cancer cells by up-regulating ICAM-1 expression
13. Dose-ranging and clinical pharmacologic study of arsenic trioxide in patients with advanced hematologic cancers
14. 3) in the treatment of acute promyelocytic leukemia (APL): II. Clinical efficacy and pharmacokinetics in relapsed patients
15. Complete remission after treatment of acute promyelocytic leukemia with arsenic trioxide
16. 3 induces NB4 cell apoptosis with downregulation of bcl-2 expression and alteration of PML-RARa/PML protein localization
17. Mechanism of arsenic trioxide induced growth inhibition and apoptosis in malignant cells
18. Apoptosis and growth inhibition in malignant lymphocytes after treatment with arsenic trioxide at clinically achievable concentrations
19. Arsenic trioxide: a novel nitochondriotoxic anticancer agent?
20. 3) in high risk refractory multiple myeloma
21. Arsenic trioxide and melarsoprol induce apoptosis in plasma cell lines and in plasma cells from myeloma patients
22. Arsenic trioxide-mediated growth inhibition of MC/CAR myeloma cells via cell cycle arrest in association with induction cyclin-dependent kinase inhibitor, p21, and apoptosis
23. Clinical trials referral resource. Clinical trials with arsenic trioxide
24. Recent advances in the treatment of multiple myeloma
25. Antitumor activity of thalidomide in refractory multiple myeloma